Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead

Executive Summary

Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.

Advertisement

Related Content

Dupixent Hits Endpoints In Adolescents, Filing Expected In Q3
AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study
Dupixent FDA Asthma Review Bolsters Sanofi And Regeneron
AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms
Dermira Takes Roche's Lebrikizumab With Best-In-Class Ambitions
Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
Galderma Steps Into Biologics With Chugai Eczema Antibody
AstraZeneca Hands LEO Dermatology Potential

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100436

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel